Northwire Canada EditionMonday, July 13, 2026
Northwire
OCG 0.280 +0.0% CAMB 1.00 +0.0% HMR 0.620 +0.0% GOFL 0.025 +0.0% SIG 1.03 +0.0% SGQ 0.300 +0.0% AMCO 0.250 +0.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.910 +0.0% SMY 0.235 +0.0% SAG 1.02 +0.0% NTH 0.165 +0.0% PEMC 0.045 +0.0% NAR 0.180 +0.0% OCG 0.280 +0.0% CAMB 1.00 +0.0% HMR 0.620 +0.0% GOFL 0.025 +0.0% SIG 1.03 +0.0% SGQ 0.300 +0.0% AMCO 0.250 +0.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.910 +0.0% SMY 0.235 +0.0% SAG 1.02 +0.0% NTH 0.165 +0.0% PEMC 0.045 +0.0% NAR 0.180 +0.0%
Financings

Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan

HEAL · Price

Executive Summary

  • Restart Life Sciences Corp. raised approximately CAD $590,000 through warrant exercises ($340k) and a CAD $250,000 loan.
  • The proceeds are earmarked to fund the planned acquisition of 100% of Holy Crap Foods Inc. and for general working capital.
  • The loan carries a 12% annual interest rate, 12‑month term, with a renewal option; warrant exercises included a $130,000 contribution from the CEO.

Key Details

  • Warrant Exercises: Holders exercised 4,103,023 warrants generating ~CAD $340,000 gross proceeds.
  • CEO Participation: The CEO exercised 1,303,023 warrants for ~CAD $130,000 of the total.
  • Loan Financing: Arm’s‑length loan of CAD $250,000 principal; 12% per annum interest payable monthly; 12‑month term with optional renewal upon mutual agreement.
  • Use of Proceeds: Net proceeds will be applied to:
  • Advance a binding Letter of Intent (dated Dec 22 2025) to acquire 100% of Holy Crap Foods Inc. from Happy Belly Food Group (CSE: HBFG).
  • Support ongoing Food Studies initiatives.
  • Provide general working capital.
  • Acquisition Conditions: Completion subject to satisfactory due diligence, execution of a definitive agreement, and regulatory approvals including CSE consent.
  • Forward‑Looking Statements: The release contains forward‑looking information regarding loan repayment, use of proceeds, and acquisition completion; risks and uncertainties are disclosed.

Notable Quotes

  • “Restart Life Sciences extends its appreciation to shareholders for their continued support as the Company advances its mission and executes on its strategic growth initiatives.” – Steve Loutskou, CEO.
Read the original news release →

More from Restart Life Sciences Corp.